keyword
MENU ▼
Read by QxMD icon Read
search

GnRH Antagonist

keyword
https://www.readbyqxmd.com/read/28540977/oral-contraceptive-pill-progestogen-or-oestrogen-pretreatment-for-ovarian-stimulation-protocols-for-women-undergoing-assisted-reproductive-techniques
#1
REVIEW
Cindy Farquhar, Luk Rombauts, Jan Am Kremer, Anne Lethaby, Reuben Olugbenga Ayeleke
BACKGROUND: Among subfertile women undergoing assisted reproductive technology (ART), hormone pills given before ovarian stimulation may improve outcomes. OBJECTIVES: To determine whether pretreatment with the combined oral contraceptive pill (COCP) or with a progestogen or oestrogen alone in ovarian stimulation protocols affects outcomes in subfertile couples undergoing ART. SEARCH METHODS: We searched the following databases from inception to January 2017: Cochrane Gynaecology and Fertility Group Specialised Register, The Cochrane Central Register Studies Online, MEDLINE, Embase, CINAHL and PsycINFO...
May 25, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28525302/treatment-of-endometriosis-associated-pain-with-elagolix-an-oral-gnrh-antagonist
#2
Hugh S Taylor, Linda C Giudice, Bruce A Lessey, Mauricio S Abrao, Jan Kotarski, David F Archer, Michael P Diamond, Eric Surrey, Neil P Johnson, Nelson B Watts, J Chris Gallagher, James A Simon, Bruce Carr, W Paul Dmowski, Nicholas Leyland, Jean P Rowan, W Rachel Duan, Juki Ng, Brittany Schwefel, James W Thomas, Rita I Jain, Kristof Chwalisz
Background Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppression in previous studies. Methods We performed two similar, double-blind, randomized, 6-month phase 3 trials (Elaris Endometriosis I and II [EM-I and EM-II]) to evaluate the effects of two doses of elagolix - 150 mg once daily (lower-dose group) and 200 mg twice daily (higher-dose group) - as compared with placebo in women with surgically diagnosed endometriosis and moderate or severe endometriosis-associated pain...
May 19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28520729/top-quality-blastocyst-formation-rates-in-relation-to-progesterone-levels-on-the-day-of-oocyte-maturation-in-gnrh-antagonist-ivf-icsi-cycles
#3
V S Vanni, E Somigliana, M Reschini, L Pagliardini, E Marotta, S Faulisi, A Paffoni, P Vigano', W Vegetti, M Candiani, E Papaleo
Cycles with progesterone elevation during controlled ovarian stimulation (COS) for IVF/ICSI are commonly managed with a "freeze-all" strategy, due to a well-recognized detrimental effect of high progesterone levels on endometrial receptivity. However, also a detrimental effect of elevated progesterone on day-3 embryo quality has recently been found with regards to top quality embryo formation rate. Because blastocyst culture and cryopreservation are largely adopted, we deemed relevant to determine whether this detrimental effect is also seen on blastocyst quality on day 5-6...
2017: PloS One
https://www.readbyqxmd.com/read/28508691/corifollitropin-alfa-compared-with-follitropin-beta-in-gnrh-antagonist-ovarian-stimulation-protocols-in-an-unselected-population-undergoing-ivf-icsi
#4
Charalampos Siristatidis, Konstantinos Dafopoulos, Nikolas Christoforidis, George Anifandis, Vasileios Pergialiotis, Nikolaos Papantoniou
Recombinant DNA technologies have produced Corifollitropin alfa (CFa) used during IVF/ICSI in order to keep the circulating FSH levels above the threshold necessary to support multi-follicular growth for a week. In this prospective case-control study, we compared 70 participants treated with 150 μg CFa combined with 150 IU of follitropin beta (study group) with 70 subfertile participants with matching baseline characteristics, conforming with the same inclusion criteria and treated with an antagonist protocol using follitropin beta (control group)...
May 16, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28508683/effectiveness-of-mild-ovarian-stimulation-versus-gnrh-agonist-protocol-in-women-undergoing-assisted-reproductive-technology-a-meta-analysis
#5
Yuan Fan, Xiaowei Zhang, Zhidong Hao, Huanfei Ding, Quanyu Chen, Li Tian
OBJECTIVE: our meta-analysis was conducted to evaluate the effectiveness of the mild ovulation induction protocol using CC/gonadotropin/GnRH antagonist compared to the conventional GnRH agonist protocol in women undergoing ART. METHOD: Six electronic databases were searched from their date of establishment until August 2016. Outcomes in our analysis were calculated in terms of relative risk (RR) and weighted mean differences (WMD) and standard mean differences (SMD) with 95% confidence intervals (CI) using random effect models or fixed effect models...
May 16, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28506467/apoptosis-of-bovine-granulosa-cells-intracellular-pathways-and-differentiation
#6
M C Carou, P R Cruzans, A Maruri, M G Farina, C D Fiorito, G Olea, D M Lombardo
Follicular atresia in granulosa and theca cells occurs by apoptosis through weak hormonal stimulation. We have previously proposed an in vitro model to study this process by inducing apoptosis in BGC-1, a bovine granulosa cell line, and in primary cultures from ovaries with or without corpus luteum (CPGB+ and CPGB-, respectively), with different doses of gonadotropin releasing hormone (GnRH) analogs (leuprolide acetate (LA) as agonist and antide as antagonist). BGC-1 represent immature granulosa cells, whereas CPGB represent different degrees of luteinization...
May 12, 2017: Acta Histochemica
https://www.readbyqxmd.com/read/28502477/knockdown-of-hepatic-gonadotropin-releasing-hormone-by-vivo-morpholino-decreases-liver-fibrosis-in-multidrug-resistance-gene-2-knockout-mice-by-down-regulation-of-mir-200b
#7
Konstantina Kyritsi, Fanyin Meng, Tianhao Zhou, Nan Wu, Julie Venter, Heather Francis, Lindsey Kennedy, Paolo Onori, Antonio Franchitto, Francesca Bernuzzi, Pietro Invernizzi, Kelly McDaniel, Romina Mancinelli, Domenico Alvaro, Eugenio Gaudio, Gianfranco Alpini, Shannon Glaser
Hepatic fibrosis occurs during the progression of primary sclerosing cholangitis (PSC) and is characterized by accumulation of extracellular matrix proteins. Proliferating cholangiocytes and activated hepatic stellate cells (HSCs) participate in the promotion of liver fibrosis during cholestasis. Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone synthesized by hypothalamic neurons and the biliary epithelium and exerts its biological effects on cholangiocytes by interaction with the receptor subtype (GnRHR1) expressed by cholangiocytes and HSCs...
May 11, 2017: American Journal of Pathology
https://www.readbyqxmd.com/read/28501366/reproductive-outcomes-after-a-single-dose-of-gonadotropin-releasing-hormone-agonist-compared-with-human-chorionic-gonadotropin-for-the-induction-of-final-oocyte-maturation-in-hyper-responder-women-aged-35-40%C3%A2-years
#8
Samer Tannus, Rola Turki, Yoni Cohen, Weon-Young Son, Tal Shavit, Michael Haim Dahan
OBJECTIVE: To investigate the reproductive outcomes after the use of GnRH agonist (GnRHa) compared with hCG for the induction of final oocyte maturation in GnRH antagonist cycles performed in hyper-responder women aged 35-40 years. DESIGN: Retrospective study. SETTING: Academic fertility center. PATIENT(S): Two hundred seventy-two hyper-responder women aged 35-40 years who underwent controlled ovarian stimulation under GnRH antagonist suppression were included...
May 10, 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/28501316/early-initiation-of-gnrh-antagonist-administration-in-a-flexible-protocol-is-it-better
#9
EDITORIAL
Li-Te Lin, Peng-Hui Wang, Kuan-Hao Tsui
No abstract text is available yet for this article.
May 10, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28480768/degarelix-versus-luteinizing-hormone-releasing-hormone-agonists-for-the-treatment-of-prostate-cancer
#10
Timothy N Clinton, Solomon L Woldu, Ganesh V Raj
Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits and disadvantages over traditional LHRH agonist therapy...
June 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28467764/anovulatory-patients-demonstrate-a-sharp-decline-in-lh-levels-upon-gnrh-antagonist-administration-during-ivf-cycles
#11
Linoy Segal, Ofer Fainaru, Shahar Kol
To evaluate the decrease in luteinizing hormone (LH) levels following gonadotropin-releasing hormone (GnRH) antagonist administration in in vitro fertilization (IVF) cycles, data were retrospectively collected from 305 consecutive IVF or intracytoplasmic sperm injection (ICSI) cycles of patients who underwent ovarian stimulation with gonadotropins and were treated with GnRH antagonist for the prevention of premature luteinization. We compared the percent change in LH concentration from stimulation start to that observed before ovulation triggering in patients with or without anovulation...
April 28, 2017: Rambam Maimonides Medical Journal
https://www.readbyqxmd.com/read/28462402/letrozole-gnrh-antagonist-stimulation-protocol-in-poor-ovarian-responders-undergoing-intracytoplasmic-sperm-injection-cycles-an-rct
#12
Mahbod Ebrahimi, Firouzeh Akbari-Asbagh, Mojgan Ghalandar-Attar
BACKGROUND: Gonadotropin-releasing hormone (GnRH) antagonist protocol has been proposed as a potentially proper option for the patients with limited ovarian reserve. Nevertheless, there is no significant difference in terms of clinical pregnancy between the GnRH antagonist and agonist cycles. The use of aromatase inhibitors such as letrozole was suggested by some studies. OBJECTIVE: The object of this study was to evaluate the efficacy of letrozole co-treatment with GnRH-antagonist protocol in ovarian stimulation of poor responder patients undergoing intracytoplasmic sperm injection...
February 2017: International Journal of Reproductive Biomedicine (Yazd, Iran)
https://www.readbyqxmd.com/read/28459828/individual-luteolysis-pattern-after-gnrh-agonist-trigger-for-final-oocyte-maturation
#13
Barbara Lawrenz, Nicolas Garrido, Suzan Samir, Francisco Ruiz, Laura Melado, Human M Fatemi
Final oocyte maturation using GnRH-agonist trigger in a GnRH-antagonist protocol is increasingly common, as ovarian hyperstimulation syndrome is almost completely avoided. However, this approach might lead to reduced pregnancy rates due to severe luteolysis. This proof of concept study evaluated the extend of luteolysis by measuring progesterone levels 48 hours after oocyte retrieval in 51 patients, who received GnRH-agonist trigger for final oocyte maturation in a GnRH-antagonist protocol due to the risk of ovarian hyperstimulation syndrome...
2017: PloS One
https://www.readbyqxmd.com/read/28459598/practices-and-attitudes-regarding-women-undergoing-fertility-preservation-a-survey-of-the-national-physicians-cooperative
#14
Pietro Bortoletto, Rafael Confino, Brigid M Smith, Teresa K Woodruff, Mary Ellen Pavone
PURPOSE: To describe physician attitudes and variations in oncofertility treatment strategies. METHODS: An exploratory online survey administered between December 1, 2014 and January 27, 2015 to 185 members of the National Physicians Cooperative (NPC). RESULTS: Twenty-eight percent (52 of 185) of NPC members responded to the online survey. Fifty percent of respondents were obstetrician-gynecologists working largely in academic medical centers...
May 1, 2017: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/28452561/follicular-growth-but-absence-of-oocyte-and-cumulus-maturation-during-ovarian-stimulation-in-the-days-following-surgical-abortion-a-case-report
#15
Clémentine Cohade, Jessika Moreau, Nicolas Gatimel, Laurence Gladieff, Jean Parinaud, Roger Leandri
This paper is a case report on the results of an ovarian stimulation performed in the days following an induced abortion. A patient had breast cancer diagnosed during an early pregnancy. She had an induced abortion and had, before chemotherapy an ovarian stimulation, using rFSH and GnRH antagonist, followed by follicular puncture for oocyte for vitrification in the view of fertility preservation. No oocyte could be obtained despite a good hormonal and ultrasonographical follicular growth. This case report suggest that ovarian stimulation must be delayed after abortion to allow the maturation of oocyte-cumulus complexes...
April 28, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28449632/predicting-the-outcome-of-different-protocols-of-in%C3%A2-vitro-fertilization-with-anti-mu%C3%A3-llerian-hormone-levels-in-patients-with-polycystic-ovary-syndrome
#16
Ya Chen, Bilv Ye, Xiaojing Yang, Jiujia Zheng, Jinju Lin, Junzhao Zhao
Objective This study evaluated associations of basal serum and follicular fluid (FF) anti-Muüllerian hormone (AMH) levels with in vitro fertilization (IVF) outcomes in polycystic ovary syndrome (PCOS) patients. Methods This prospective study included 179 consecutive women undergoing IVF, including 59 with PCOS and non-PCOS controls. Thirty PCOS cases had long gona-dotrophin-releasing hormone agonist (GnRH-a) and 29 had antagonist (GnRH-ant) protocols. Controls underwent conventional GnRH-a. Associations of basal serum and FF AMH levels with IVF outcomes were assessed...
January 1, 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28447505/does-pituitary-suppression-affect-live-birth-rate-in-women-with-congenital-hypogonadotrophic-hypogonadism-undergoing-intra-cytoplasmic-sperm-injection-a-multicenter-cohort-study
#17
Sezcan Mumusoglu, Baris Ata, Volkan Turan, Berfu Demir, Inci Kahyaoglu, Kiper Aslan, Ayse Seyhan Ata, Bulent Yilmaz, Kayhan Yakin, Berrin Avci, Gurkan Uncu, Gurkan Bozdag
In this retrospective multicenter cohort study, women with congenital hypogonadotrophic hypogonadism (CHH) (n = 57) who underwent intra-cytoplasmic sperm injection in-between 2010-2014 were compared to age-matched controls with tubal factor infertility (n = 114) to assess ovarian stimulation cycle and pregnancy outcomes. Live birth rates (LBRs) per started cycle were 31.6 and 24.6% in CHH and controls groups, respectively (p = 0.36). Comparable success rates were also confirmed with the logistic regression analysis (OR: 1...
April 27, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28441891/investigational-and-experimental-gnrh-analogs-and-associated-neurotransmitters
#18
Zeev Blumenfeld
The GnRH agonistic analogs enable for desensitizing the hypothalamo-pituitary-gonadal axis in malignant and benign conditions where minimizing the production of sex hormones, or blocking ovulation is necessary. The possible indications are prostate cancer, benign prostate hyperplasia, breast cancer, endometriosis, precocious puberty, uterine leiomyomata, assisted reproduction (ART)/in vitro fertilization (IVF), PCOS, minimizing the gonadotoxic effect of chemotherapy in young women, and possibly ovarian cancer...
May 4, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28440715/gnrh-agonist-triggering-for-final-oocyte-maturation-in-gnrh-antagonist-ivf-cycles-induces-decreased-lh-pulse-rate-and-amplitude-in-early-luteal-phase-a-possible-luteolysis-mechanism
#19
Samer Tannus, Yechiel Burke, Christopher R McCartney, Shahar Kol
The use of GnRH agonist to trigger final oocyte maturation in GnRH-antagonist in vitro fertilization (IVF) cycles has been shown to significantly reduce or even eliminate the risk of ovarian hyperstimulation syndrome (OHSS) by inducing rapid luteolysis early in the luteal phase. The exact mechanism of this early luteolysis is still widely unknown. Since luteinizing hormone (LH) has a major role in corpus luteum support, we sought to explore the pattern of LH secretion early in the luteal phase. Ten high risk patients for developing OHSS and triggered with GnRH agonist were included...
April 25, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28437434/comparisons-of-gnrh-antagonist-protocol-versus-gnrh-agonist-long-protocol-in-patients-with-normal-ovarian-reserve-a-systematic-review-and-meta-analysis
#20
Ruolin Wang, Shouren Lin, Yong Wang, Weiping Qian, Liang Zhou
OBJECTIVE: To evaluate the effectiveness and safety of gonadotropin-releasing hormone antagonist (GnRH-ant) protocol and gonadotropin-releasing hormone agonist (GnRH-a) long protocol in patients with normal ovarian reserve. METHODS: We searched the PubMed (1992-2016), Cochrane Library (1999-2016), Web of Science (1950-2016), Chinese Biomedical Database (CBM, 1979-2016), and China National Knowledge Infrastructure (CNKI, 1994-2016). Any randomized controlled trials (RCTs) that compared GnRH-ant protocol and GnRH-a long protocol in patients with normal ovarian reserve were included, and data were extracted independently by two reviewers...
2017: PloS One
keyword
keyword
22470
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"